"Lenperone"

and in vitro studies.Intervention(s), exposure(s)Inclusion criteria:We will include any antipsychotic (i.e., acepromazine, acetophenazine, benperidol, bromperidol, butaperazine, carfenazine, chlorproethazine, chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, dixyrazine, droperidol, fluanisone, flupentixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, lenperone, loxapine, mesoridazine

Antipsychotic effects, side effects and effective dosis of the butyrophenone lenperone (AHR 2277). Three open studies with Lenperone were performed. 50 hospitalized schizophrenic patients were treated 20-30 days with Lenperone. The therapeutic effective dose was 30-50 mg/day. The highest daily dosage was 90 mg. Patients were examined on fixed observation days and the findings were documented by means of the AMP system. AMP data were analyzed at symptom and syndrome level and compared using an analysis of covariance. In the described dosage Lenperone acted only little sedating, strong antipsychotic and caused only a few single extrapyramidal and little autonomic side effects. The dosage is limited because of the effect on heart and blood circulation. Lenperone caused a good improvement

as determined by esophageal manometry. The number of swallows required for acid clearance varied from four to 12 with a mean of 8 +/- 1.8. The time required for acid clearance varied from 150 to 480 s with a mean of 285 +/- 75. No significant difference was noted after 0.16 mg/kg of lenperone hydrochloride was given intramuscularly. The esophageal acid clearance test in dogs appears similar to that reported

Effect of lenperone hydrochloride on gastroesophageal sphincter pressure in healthy dogs. Treatment of healthy dogs with the butyrophenone derivative, lenperone hydrochloride, at two different doses significantly decreased gastroesophageal sphincter pressure (GESP). No dose-related effect was identified. Individual variation in the response to lenperone hydrochloride was noted which was consistent on a day-to-day basis. Lenperone hydrochloride is unsuitable for chemical restraint of dogs undergoing esophageal manometry because it decreases GESP and because the magnitude of the decrease varies considerably between dogs.